|
1）Campbell R Jr, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum. 2008; 59: 458-64
|
|
|
|
2）Guidelines for referral and management of systemic lupus erythematosus in adults. American college of Rheumatology ad hoc committee on SLE guidelines. Arthritis Rheum. 1999, 42: 1785-96
|
|
|
|
|
|
3）Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64: 797-808
|
|
|
|
|
|
4）Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012; 71:1771-82
|
|
|
|
|
|
5）Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15: 241-50
|
|
|
|
|
|
6）KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Sup. 2012; 2: 221-32
|
|
|
|
|
|
7）Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20: 1103-12
|
|
|
|
|
|
8）Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011; 57: 235-44
|
|
|
|
|
|
9）Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009; 19:606-15
|
|
|
|
|
10）Doopley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011; 365: 1886-95
|
|
|
|
|
|
11）Feng L, Deng J, Huo DM, et al. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton). 2013; 18:104-10
|
|
|
|
|
|
12）Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008; 19: 2001-10
|
|
|
|
|
|
13）Kagawa H, Hiromasa T, Hara T, et al. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis. Clin Exp Nephrol. 2012; 16: 760-6
|
|
|
|
|
|
14）Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. Arthritis Rheum. 2012; 64: 1215-26
|
|
|
|
|
|
15）Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377:721-31
|
|
|
|
|